< View all reports

Inflammatory Bowel Disease Market Report

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026

Despite the forthcoming wave of ulcerative colitis drugs, opportunities will remain for pharma.

This Inflammatory Bowel Disease market report covers key topics such as current treatment options, unmet needs and opportunities, and the drivers and barriers affecting Ulcerative Colitis (UC) therapeutics sales in the 7MM. Over the course of the forecast period, the UC market is expected to grow at a Compound Annual Growth Rate (CAGR) of 2.5%. By the end of 2026, the US will account for 80.4% of drug sales, while the 5EU and Japan will account for around 16.1% and 3.4% of sales, respectively.

  • Why should you buy this report?
  • Identify companies with the most robust pipeline
  • Understand the trends shaping the UC therapeutics market
  • Recognize innovative products and technologies, market segments, and companies most likely to impact the UC therapeutics market in future
  • Analyze competitor performance
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage

How will the UC market landscape change from 2016–2026?

Major drivers of growth in the UC market over the forecast period will include an increase in disease prevalence in 6 of the 7 major markets, higher treatment rates, the approval and launch of 10 pipeline products, and the high unmet need for novel oral therapies.

Key opinion leaders interviewed by GlobalData discussed a need for novel oral therapies in the UC space. At present, only one oral therapy has been approved in the US: Pfizer’s first-in-class Janus kinase (JAK) inhibitor, Xeljanz (Tofacitinib). Xeljanz is likely to receive approval in both Japan and Europe, and GlobalData expects that there will be four more oral therapies approved over the next 5 years.

Despite this, opportunity still exists in the market. Oral therapies are favoured over other routes of administration due to the ease of administration. Yet, all therapies currently under development have their particular weaknesses with regards to safety and speed of action. Additionally, there are no new oral MOAs for severe-to-fulminant UC patients, which creates further opportunity for pharmaceutical companies.

Purchase Today

Single user $ 10,995

Buy Now


+44 (0) 161 359 5813

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026

Not ready to buy yet? Download our free report series guide on IBD

I consent to GlobalData collecting my details provided via this form.

You are in control of the communications you receive from us and you can update your preferences anytime to make sure you are receiving information that matters to you. Please check our GlobalData Privacy Policy to see how we protect and manage your submitted data.